Home LiteratureArticle Details
PMID: 16108013 Published · ppublish English Journal Article

Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.

International journal of cancer ·Vol. 118 ·No. 4 ·2006-02-15 ·Pages 812-20

Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K

Abstract

Survivin is a member of the inhibitor of apoptosis protein (IAP) family that is specifically overexpressed in cancer tissues. p53 is one of the tumor suppressor genes; its induction in response to DNA damage causes apoptosis and correlates with drug sensitivity. To investigate the possible regulation of survivin by p53, we examined the level of survivin expression in lung cancer cell lines in response to adriamycin. Levels of survivin mRNA and protein in cell lines with wild-type p53 decreased dramatically after p53 induction, but no such reduction of survivin was observed in cell lines with mutated or null p53. Inhibition of wild-type p53 in A549 cells by small interfering (si) RNA significantly upregulated the expression of survivin. Survivin inhibition by siRNA in PC9 cells with mutated p53 significantly depressed cell proliferation. To investigate the sensitivity of cancer cells to adriamycin after inhibition of survivin, we depressed survivin expression using siRNA, and then added adriamycin at an IC50 dose. After a further 48 hr incubation with adriamycin, proliferation was significantly depressed in the cells treated with siRNA targeting survivin, in comparison with siRNA targeting scramble. Furthermore, both TUNEL and pro-caspase3 expression assay showed a significant increase in apoptosis after combined treatment with adriamycin and siRNA targeting survivin. Our results demonstrate that survivin is downregulated by p53, and that siRNA targeting of survivin increases cell sensitivity to adriamycin and promotes apoptosis. siRNA targeting of survivin could be potentially useful for increasing sensitivity to anticancer drugs, especially in drug-resistant cells with mutated p53.

MeSH Terms
Antibiotics, Antineoplastic/pharmacology Apoptosis/drug effects,genetics Doxorubicin/pharmacology Gene Expression Regulation, Neoplastic Genes, p53 Humans In Situ Nick-End Labeling Inhibitor of Apoptosis Proteins Lung Neoplasms/genetics,pathology Microtubule-Associated Proteins/biosynthesis Mutation Neoplasm Proteins/biosynthesis RNA, Small Interfering Reverse Transcriptase Polymerase Chain Reaction Survivin Tumor Cells, Cultured Up-Regulation
Chemicals
Antibiotics, Antineoplastic BIRC5 protein, human Inhibitor of Apoptosis Proteins Microtubule-Associated Proteins Neoplasm Proteins RNA, Small Interfering Survivin Doxorubicin
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Yonesaka Kimio
Department of Medical Oncology, Kinki University School of Medicine, Osaka-sayama, Osaka, Japan.
Tamura Kenji
Kurata Takayasu
Satoh Taroh
Ikeda Masato
Fukuoka Masahiro
Nakagawa Kazuhiko
Article Info
Journal
International journal of cancer
Abbr.
Int J Cancer
ISSN
0020-7136
Published
2006-02-15
Pages
812-20
Language
English
Region
United States
NLM ID
0042124
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com